Report: Potential COVID Vaccine To Enter Final Testing In July
A potential coronavirus vaccine developed by Moderna is slated to enter its final testing stage in July, The Hill confirmed on Wednesday.
- The Wall Street Journal first reported that John Mascola, the director of the vaccine research center at the National Institute of Allergy and Infectious Diseases (NIAID), said trials will involve around 30,000 people at more than 50 sites, most of which will be located in the United States.
- The Hill noted that a Moderna spokesperson confirmed to The Journal that the company plans trials in July.
- Potential vaccines developed by Oxford University and AstraZeneca are also expected to head to a third phase of trials in August.
- Another potential vaccine from Johnson & Johnson is scheduled for final trials in September.
- In a statement, NIAID said approval from the Food and Drug Administration is one of “several factors” that will determine trial timelines.
The testing, which will be funded by the federal government, is designed to determine each vaccine’s safety and effectiveness. A vaccine would be considered successful if those who take it contract the virus and develop COVID-19 at lower rates than those who take a placebo.
Public health officials have emphasized the need for at least one vaccine that could prevent infections or at least lessen the severity of COVID-19 in order for Americans to resume normal activities.